SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“We conducted this phase 3 clinical trial to try to see if we could enhance the expediency of the infusion experience for patients who are on subcutaneous immunoglobulin,” Joanna Maltese, BSN, RN, clinical nurse educator at Octapharma, told Healio.
The researchers designed three modified infusion regimens for Cutaquig (Octapharma AG), which is a 16.5%